Brett Dovman

Cooley advised TriSalus Life Sciences, an oncology company with a focus on treatments for patients with liver and pancreatic tumors, on its merger with MedTech Acquisition Corporation.

Cooley advised NKGen Biotech, a clinical-stage biotechnology company, on its business combination agreement with special purpose acquisition company Graf Acquisition Corp. IV – a combination that will result in NKGen becoming a publicly listed company.

Cooley advised Ambrx Biopharma on its $126 million initial public offering of 7,000,000 American depositary shares, each representing seven ordinary shares. Ambrx Biopharma, whose securities now trade on the New York Stock Exchange under the symbol AMAM, is a clinical-stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop engineered precision biologics. Partners Charlie Kim, Patrick Loofbourrow, Sean Clayton and Will Cai led the Cooley team.

Cooley advised MannKind on its offering of $200 million principal amount of 2.50% convertible senior notes due 2026. MannKind, whose securities trade on the Nasdaq Global Market under the symbol MNKD, focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Partners Sean Clayton, Mischi a Marca and Jason Savich led the Cooley team.

Cooley advised Silverback Therapeutics on its $277.7 million initial public offering of 13,225,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Silverback Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol SBTX, is a biopharmaceutical company that develops proprietary ImmunoTAC therapies targeting previously inaccessible disease pathways. Partners Ken Rollins and Charlie Kim led the Cooley team.